Prospects for an Anticancer Vaccine
October 17, 2023 | Terry Sharrer
“Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response. If validated in clinical trials, the technology could help scientists overcome a major hurdle to developing personalized immunotherapies and vaccines. . . . . the cancer protein fragments that elicit this tumor-killing immune response may originate from changes in the genetic makeup of cancer cells (or mutations), called mutation-associated neoantigens.” MORE